Another TreatSMA Trustee to be on the Risdiplam Appraisal

Two of the three available seats for patient experts taken by TreatSMA trustees for the Risdiplam appraisal taking place on the 11th May 2021.

On the 11th of May, Trustees Lucy and Andi will represent the real community experience as TreatSMA nominees as we believe that both adults and parents should have a voice. Andi has lived with SMA all his life and deeply understands what it is like and his account will be based on first hand experience (not simple repetition of other people words). Equally, Lucy, a mother to child who lived through no treatment, and is now benefiting from the treatment, offers a parent’s perspective.

We are pleased that we are able to represent the community from both perspectives and we know both Lucy and Andi will fight for all during the appraisal.

We represent the community because we are the community.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more